 Timothy Benke
Concepts (491)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 26 | 2024 | 104 | 6.600 |
Why?
| | Epileptic Syndromes | 21 | 2024 | 63 | 5.560 |
Why?
| | Seizures | 17 | 2023 | 345 | 3.460 |
Why?
| | Rett Syndrome | 16 | 2024 | 23 | 3.130 |
Why?
| | Epilepsy | 12 | 2023 | 290 | 2.980 |
Why?
| | Receptors, AMPA | 13 | 2023 | 125 | 2.360 |
Why?
| | Hippocampus | 20 | 2023 | 735 | 2.250 |
Why?
| | Long-Term Potentiation | 9 | 2022 | 148 | 1.790 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 11 | 2023 | 191 | 1.720 |
Why?
| | Vision Disorders | 8 | 2023 | 135 | 1.670 |
Why?
| | Movement Disorders | 5 | 2023 | 45 | 1.430 |
Why?
| | Synapses | 13 | 2023 | 344 | 1.430 |
Why?
| | Excitatory Postsynaptic Potentials | 11 | 2018 | 105 | 1.240 |
Why?
| | Cognition Disorders | 8 | 2019 | 529 | 1.070 |
Why?
| | Anticonvulsants | 6 | 2023 | 184 | 1.020 |
Why?
| | Long-Term Synaptic Depression | 3 | 2014 | 51 | 0.970 |
Why?
| | CA1 Region, Hippocampal | 3 | 2022 | 30 | 0.970 |
Why?
| | Neuropsychological Tests | 16 | 2020 | 1032 | 0.960 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2020 | 17 | 0.950 |
Why?
| | Neurodevelopmental Disorders | 3 | 2021 | 116 | 0.940 |
Why?
| | Receptors, Metabotropic Glutamate | 2 | 2014 | 35 | 0.940 |
Why?
| | Autistic Disorder | 3 | 2022 | 168 | 0.910 |
Why?
| | Social Behavior | 3 | 2015 | 276 | 0.890 |
Why?
| | Kainic Acid | 9 | 2020 | 32 | 0.890 |
Why?
| | Memory Disorders | 4 | 2014 | 167 | 0.790 |
Why?
| | Clinical Trials as Topic | 3 | 2022 | 969 | 0.740 |
Why?
| | Genetic Therapy | 1 | 2021 | 267 | 0.720 |
Why?
| | Developmental Disabilities | 2 | 2019 | 247 | 0.700 |
Why?
| | Rats, Sprague-Dawley | 12 | 2021 | 2478 | 0.660 |
Why?
| | Maze Learning | 3 | 2014 | 86 | 0.660 |
Why?
| | Neuronal Plasticity | 3 | 2018 | 219 | 0.650 |
Why?
| | Symptom Assessment | 1 | 2019 | 123 | 0.630 |
Why?
| | Mental Retardation, X-Linked | 3 | 2023 | 13 | 0.610 |
Why?
| | Cerebral Cortex | 7 | 2021 | 416 | 0.590 |
Why?
| | Schizophrenia | 1 | 2021 | 501 | 0.580 |
Why?
| | Rats | 19 | 2021 | 5392 | 0.580 |
Why?
| | Genomics | 1 | 2021 | 706 | 0.570 |
Why?
| | Hair Cells, Vestibular | 4 | 2023 | 27 | 0.540 |
Why?
| | Methyl-CpG-Binding Protein 2 | 5 | 2023 | 11 | 0.530 |
Why?
| | Animals | 38 | 2023 | 33381 | 0.530 |
Why?
| | Humans | 86 | 2024 | 118931 | 0.510 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2673 | 0.490 |
Why?
| | Dementia | 4 | 2007 | 208 | 0.480 |
Why?
| | Animals, Newborn | 9 | 2015 | 806 | 0.480 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 152 | 0.460 |
Why?
| | Electroencephalography | 12 | 2023 | 387 | 0.460 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 4 | 2016 | 159 | 0.460 |
Why?
| | Disease Models, Animal | 8 | 2022 | 3730 | 0.450 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1597 | 0.450 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2013 | 65 | 0.440 |
Why?
| | Child | 30 | 2024 | 19128 | 0.440 |
Why?
| | Male | 52 | 2023 | 57784 | 0.420 |
Why?
| | Behavior, Animal | 1 | 2015 | 486 | 0.400 |
Why?
| | Glutamic Acid | 4 | 2007 | 224 | 0.390 |
Why?
| | Female | 50 | 2023 | 61547 | 0.380 |
Why?
| | Nervous System Diseases | 2 | 2023 | 261 | 0.380 |
Why?
| | Quality of Life | 6 | 2023 | 2363 | 0.370 |
Why?
| | Ion Channels | 4 | 2012 | 126 | 0.370 |
Why?
| | Chromosome Duplication | 2 | 2020 | 4 | 0.370 |
Why?
| | Calcium Channels, L-Type | 3 | 2022 | 110 | 0.350 |
Why?
| | Child, Preschool | 17 | 2024 | 9491 | 0.350 |
Why?
| | Basal Ganglia Diseases | 2 | 2009 | 7 | 0.340 |
Why?
| | Excitatory Amino Acid Agonists | 4 | 2015 | 39 | 0.340 |
Why?
| | Surveys and Questionnaires | 7 | 2023 | 4705 | 0.320 |
Why?
| | Space Perception | 1 | 2008 | 65 | 0.320 |
Why?
| | Genetic Association Studies | 2 | 2020 | 371 | 0.320 |
Why?
| | Risk-Taking | 2 | 2009 | 319 | 0.310 |
Why?
| | Evoked Potentials, Visual | 3 | 2023 | 31 | 0.310 |
Why?
| | Brain Ischemia | 2 | 2009 | 310 | 0.300 |
Why?
| | Dystonia | 1 | 2007 | 14 | 0.300 |
Why?
| | Psychometrics | 5 | 2024 | 631 | 0.300 |
Why?
| | Mutation | 10 | 2023 | 3457 | 0.300 |
Why?
| | Memory, Short-Term | 2 | 2008 | 233 | 0.300 |
Why?
| | Neurons | 7 | 2023 | 1345 | 0.290 |
Why?
| | Models, Neurological | 6 | 2005 | 216 | 0.290 |
Why?
| | Membrane Potentials | 6 | 2023 | 253 | 0.290 |
Why?
| | Brain Abscess | 1 | 2006 | 11 | 0.290 |
Why?
| | Calcium | 6 | 2023 | 1169 | 0.280 |
Why?
| | Infant | 15 | 2024 | 8293 | 0.280 |
Why?
| | Amnesia | 2 | 2005 | 46 | 0.280 |
Why?
| | Indans | 1 | 2005 | 9 | 0.270 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 26 | 0.270 |
Why?
| | Prosencephalon | 1 | 2005 | 50 | 0.270 |
Why?
| | Age Factors | 5 | 2020 | 2995 | 0.270 |
Why?
| | Evoked Potentials | 3 | 2023 | 115 | 0.270 |
Why?
| | Amobarbital | 1 | 2005 | 1 | 0.270 |
Why?
| | Amnesia, Transient Global | 1 | 2005 | 1 | 0.270 |
Why?
| | Aneurysm, Ruptured | 1 | 2005 | 38 | 0.260 |
Why?
| | Phenotype | 8 | 2022 | 3003 | 0.260 |
Why?
| | Long QT Syndrome | 2 | 2022 | 57 | 0.260 |
Why?
| | Tissue Culture Techniques | 2 | 2015 | 67 | 0.260 |
Why?
| | Patch-Clamp Techniques | 8 | 2015 | 247 | 0.250 |
Why?
| | Brain Diseases | 3 | 2023 | 140 | 0.250 |
Why?
| | Tetanus Toxin | 1 | 2004 | 5 | 0.240 |
Why?
| | Neurodegenerative Diseases | 1 | 2006 | 99 | 0.240 |
Why?
| | Piperidines | 1 | 2005 | 171 | 0.240 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 136 | 0.240 |
Why?
| | Adolescent | 21 | 2024 | 18480 | 0.240 |
Why?
| | Celiac Disease | 1 | 2007 | 267 | 0.240 |
Why?
| | Parvalbumins | 1 | 2023 | 19 | 0.240 |
Why?
| | Decision Making | 2 | 2009 | 807 | 0.230 |
Why?
| | Status Epilepticus | 1 | 2023 | 36 | 0.230 |
Why?
| | Signal Transduction | 2 | 2014 | 4709 | 0.230 |
Why?
| | Cerebral Aqueduct | 1 | 2003 | 3 | 0.230 |
Why?
| | Dendrites | 3 | 2007 | 88 | 0.230 |
Why?
| | Chromosomes, Human, X | 2 | 2023 | 58 | 0.230 |
Why?
| | Ventriculostomy | 1 | 2003 | 19 | 0.230 |
Why?
| | Learning | 1 | 2007 | 374 | 0.220 |
Why?
| | Vestibule, Labyrinth | 1 | 2023 | 54 | 0.220 |
Why?
| | Pregnanolone | 1 | 2022 | 21 | 0.210 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 26 | 0.210 |
Why?
| | Adult | 26 | 2024 | 31508 | 0.210 |
Why?
| | Anti-Anxiety Agents | 1 | 2022 | 38 | 0.210 |
Why?
| | Hydrocephalus | 1 | 2003 | 81 | 0.210 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 89 | 0.210 |
Why?
| | Phosphorylation | 3 | 2015 | 1633 | 0.210 |
Why?
| | Acute Disease | 4 | 2015 | 940 | 0.200 |
Why?
| | Neurologists | 1 | 2021 | 19 | 0.200 |
Why?
| | Ultrasonics | 1 | 2021 | 53 | 0.200 |
Why?
| | Calcinosis | 1 | 2004 | 282 | 0.200 |
Why?
| | Synaptic Transmission | 4 | 2023 | 239 | 0.200 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 24 | 0.200 |
Why?
| | Vision, Ocular | 1 | 2021 | 32 | 0.200 |
Why?
| | Visual Pathways | 1 | 2021 | 43 | 0.200 |
Why?
| | Corpus Callosum | 2 | 2019 | 57 | 0.200 |
Why?
| | Alzheimer Disease | 1 | 2007 | 513 | 0.200 |
Why?
| | Memory | 3 | 2008 | 230 | 0.200 |
Why?
| | Pyramidal Cells | 3 | 2015 | 54 | 0.190 |
Why?
| | Intellectual Disability | 1 | 2022 | 136 | 0.190 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2020 | 24 | 0.190 |
Why?
| | Athletic Injuries | 1 | 2007 | 495 | 0.190 |
Why?
| | Subcellular Fractions | 2 | 2013 | 84 | 0.190 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 27 | 0.190 |
Why?
| | Brain | 9 | 2009 | 2489 | 0.190 |
Why?
| | In Vitro Techniques | 6 | 2013 | 1094 | 0.190 |
Why?
| | Epilepsy, Temporal Lobe | 3 | 2005 | 20 | 0.190 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 323 | 0.190 |
Why?
| | Endoscopy | 1 | 2003 | 272 | 0.190 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 117 | 0.190 |
Why?
| | Electrophysiology | 5 | 2007 | 204 | 0.180 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4596 | 0.180 |
Why?
| | Cyclins | 1 | 2020 | 82 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 10 | 2010 | 3174 | 0.180 |
Why?
| | Pediatrics | 1 | 2007 | 985 | 0.180 |
Why?
| | Analysis of Variance | 5 | 2009 | 1293 | 0.180 |
Why?
| | Action Potentials | 6 | 2023 | 420 | 0.170 |
Why?
| | Parkinson Disease | 5 | 2011 | 334 | 0.170 |
Why?
| | Blotting, Western | 2 | 2015 | 1194 | 0.170 |
Why?
| | Speech Disorders | 1 | 2019 | 35 | 0.170 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 24 | 0.170 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 32 | 0.170 |
Why?
| | Gene Duplication | 1 | 2019 | 64 | 0.170 |
Why?
| | Double-Blind Method | 5 | 2023 | 1687 | 0.170 |
Why?
| | Glutamates | 3 | 2023 | 60 | 0.170 |
Why?
| | Syndrome | 3 | 2020 | 344 | 0.170 |
Why?
| | Face | 1 | 2020 | 165 | 0.170 |
Why?
| | Motor Activity | 2 | 2020 | 660 | 0.170 |
Why?
| | Child Behavior | 1 | 2020 | 212 | 0.160 |
Why?
| | Stroke | 1 | 2007 | 1047 | 0.160 |
Why?
| | Sleep Wake Disorders | 1 | 2022 | 240 | 0.160 |
Why?
| | Delphi Technique | 1 | 2019 | 164 | 0.160 |
Why?
| | Judgment | 1 | 2018 | 59 | 0.160 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 68 | 0.150 |
Why?
| | Aphasia | 3 | 2004 | 23 | 0.150 |
Why?
| | Alternative Splicing | 1 | 2019 | 193 | 0.150 |
Why?
| | Syncope, Vasovagal | 1 | 1997 | 3 | 0.150 |
Why?
| | Treatment Outcome | 7 | 2023 | 9341 | 0.150 |
Why?
| | Delusions | 1 | 1997 | 12 | 0.150 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 187 | 0.150 |
Why?
| | Epilepsy, Generalized | 1 | 1997 | 14 | 0.150 |
Why?
| | Memantine | 2 | 2012 | 18 | 0.150 |
Why?
| | Epilepsies, Partial | 1 | 1997 | 28 | 0.150 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 499 | 0.140 |
Why?
| | Genetic Variation | 1 | 2021 | 926 | 0.140 |
Why?
| | Mice | 7 | 2023 | 15520 | 0.140 |
Why?
| | Protein Conformation | 1 | 2019 | 848 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 278 | 0.140 |
Why?
| | Time | 1 | 2015 | 77 | 0.140 |
Why?
| | Sex Factors | 2 | 2019 | 1781 | 0.130 |
Why?
| | Brain Damage, Chronic | 1 | 1995 | 24 | 0.130 |
Why?
| | Time Factors | 9 | 2009 | 6409 | 0.130 |
Why?
| | Lyme Disease | 1 | 1995 | 32 | 0.130 |
Why?
| | Precision Medicine | 1 | 2019 | 363 | 0.130 |
Why?
| | Organ Culture Techniques | 2 | 2016 | 149 | 0.130 |
Why?
| | Reproducibility of Results | 4 | 2024 | 2874 | 0.130 |
Why?
| | N-Methylaspartate | 2 | 1996 | 38 | 0.130 |
Why?
| | Meningitis, Bacterial | 1 | 1995 | 51 | 0.130 |
Why?
| | Anxiety | 3 | 2022 | 844 | 0.130 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 21 | 0.120 |
Why?
| | Membrane Proteins | 3 | 2010 | 1055 | 0.120 |
Why?
| | Calmodulin | 1 | 2014 | 73 | 0.120 |
Why?
| | Mental Recall | 3 | 2007 | 180 | 0.120 |
Why?
| | Conotoxins | 1 | 1993 | 4 | 0.120 |
Why?
| | Mutation, Missense | 3 | 2023 | 300 | 0.120 |
Why?
| | Models, Molecular | 1 | 2019 | 1435 | 0.120 |
Why?
| | Spasm | 2 | 2023 | 19 | 0.120 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 139 | 0.120 |
Why?
| | Pregnancy | 3 | 2013 | 5690 | 0.120 |
Why?
| | Demyelinating Diseases | 1 | 1994 | 79 | 0.120 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 37 | 0.120 |
Why?
| | Protein Phosphatase 2 | 1 | 2013 | 35 | 0.120 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 160 | 0.120 |
Why?
| | Angiostrongylus cantonensis | 1 | 2013 | 3 | 0.110 |
Why?
| | Strongylida Infections | 1 | 2013 | 6 | 0.110 |
Why?
| | Young Adult | 7 | 2024 | 10793 | 0.110 |
Why?
| | Retrospective Studies | 7 | 2023 | 12972 | 0.110 |
Why?
| | Down Syndrome | 2 | 2022 | 356 | 0.110 |
Why?
| | Middle Aged | 14 | 2018 | 27607 | 0.110 |
Why?
| | Caregivers | 3 | 2023 | 705 | 0.110 |
Why?
| | Thiazoles | 1 | 2013 | 121 | 0.110 |
Why?
| | Functional Laterality | 4 | 2009 | 208 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 292 | 0.110 |
Why?
| | Meningitis | 1 | 2013 | 74 | 0.100 |
Why?
| | Presynaptic Terminals | 2 | 2009 | 58 | 0.100 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 43 | 0.100 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 368 | 0.100 |
Why?
| | Disks Large Homolog 4 Protein | 2 | 2009 | 18 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2011 | 85 | 0.100 |
Why?
| | Eosinophilia | 1 | 2013 | 184 | 0.100 |
Why?
| | Genotype | 3 | 2022 | 1881 | 0.100 |
Why?
| | Infant, Newborn | 3 | 2022 | 5255 | 0.090 |
Why?
| | Leukoencephalopathies | 1 | 2010 | 32 | 0.090 |
Why?
| | Dominance, Cerebral | 1 | 1989 | 53 | 0.090 |
Why?
| | Pyridines | 1 | 2013 | 440 | 0.090 |
Why?
| | Guanylate Kinases | 1 | 2009 | 14 | 0.090 |
Why?
| | Cysts | 1 | 2010 | 93 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 827 | 0.090 |
Why?
| | Thrombophilia | 1 | 2009 | 68 | 0.090 |
Why?
| | Prognosis | 3 | 2022 | 3440 | 0.090 |
Why?
| | Mathematical Concepts | 1 | 2009 | 24 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1384 | 0.090 |
Why?
| | Language Disorders | 2 | 2007 | 32 | 0.080 |
Why?
| | Reaction Time | 2 | 2009 | 392 | 0.080 |
Why?
| | Aged | 10 | 2022 | 19644 | 0.080 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 46 | 0.080 |
Why?
| | Uncertainty | 1 | 2009 | 101 | 0.080 |
Why?
| | A Kinase Anchor Proteins | 1 | 2009 | 72 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2006 | 3171 | 0.080 |
Why?
| | Gerbillinae | 3 | 2017 | 63 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2009 | 404 | 0.080 |
Why?
| | Exploratory Behavior | 1 | 2008 | 90 | 0.080 |
Why?
| | Conditioning, Classical | 1 | 2008 | 89 | 0.080 |
Why?
| | Cells, Cultured | 7 | 2017 | 4076 | 0.080 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 19 | 0.080 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2007 | 7 | 0.080 |
Why?
| | Shy-Drager Syndrome | 1 | 2007 | 1 | 0.080 |
Why?
| | Neuromuscular Diseases | 1 | 2008 | 90 | 0.080 |
Why?
| | Jejunum | 1 | 2007 | 30 | 0.080 |
Why?
| | Games, Experimental | 1 | 2007 | 13 | 0.080 |
Why?
| | Periodicity | 1 | 2007 | 56 | 0.070 |
Why?
| | Glutens | 1 | 2007 | 56 | 0.070 |
Why?
| | Strontium | 3 | 2017 | 14 | 0.070 |
Why?
| | Fibroblasts | 1 | 2011 | 842 | 0.070 |
Why?
| | Soccer | 1 | 2007 | 39 | 0.070 |
Why?
| | Cross-Linking Reagents | 1 | 2007 | 186 | 0.070 |
Why?
| | Antibodies | 1 | 2008 | 392 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 6471 | 0.070 |
Why?
| | Football | 1 | 2007 | 89 | 0.070 |
Why?
| | Bumetanide | 1 | 2005 | 2 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2007 | 227 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2007 | 509 | 0.070 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 12 | 0.070 |
Why?
| | Organ of Corti | 1 | 2005 | 14 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1691 | 0.070 |
Why?
| | Pilot Projects | 2 | 2012 | 1418 | 0.070 |
Why?
| | Fear | 1 | 2008 | 306 | 0.070 |
Why?
| | Length of Stay | 1 | 2010 | 1032 | 0.070 |
Why?
| | Receptors, Kainic Acid | 1 | 2005 | 10 | 0.070 |
Why?
| | Biomarkers | 2 | 2021 | 3588 | 0.070 |
Why?
| | Language | 1 | 2008 | 271 | 0.070 |
Why?
| | Diuretics | 1 | 2005 | 76 | 0.070 |
Why?
| | Hair Cells, Auditory | 1 | 2005 | 39 | 0.070 |
Why?
| | Auditory Pathways | 1 | 2005 | 54 | 0.070 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 499 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 403 | 0.060 |
Why?
| | Parents | 2 | 2023 | 1212 | 0.060 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 58 | 0.060 |
Why?
| | Ion Channel Gating | 1 | 2005 | 85 | 0.060 |
Why?
| | Thalamus | 1 | 2005 | 80 | 0.060 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 44 | 0.060 |
Why?
| | Simplexvirus | 1 | 2004 | 86 | 0.060 |
Why?
| | Nerve Net | 1 | 2007 | 232 | 0.060 |
Why?
| | Sodium | 1 | 2005 | 200 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2004 | 90 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2023 | 2680 | 0.060 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 31 | 0.060 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2004 | 131 | 0.060 |
Why?
| | Failure to Thrive | 1 | 2023 | 31 | 0.060 |
Why?
| | Protein Binding | 3 | 2016 | 1975 | 0.060 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2023 | 65 | 0.060 |
Why?
| | Thirst | 1 | 2003 | 5 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 736 | 0.060 |
Why?
| | Stereotypic Movement Disorder | 1 | 2003 | 7 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2004 | 194 | 0.060 |
Why?
| | Vigabatrin | 1 | 2023 | 18 | 0.060 |
Why?
| | Drinking | 1 | 2003 | 36 | 0.060 |
Why?
| | Biopsy | 1 | 2007 | 1079 | 0.060 |
Why?
| | Electric Conductivity | 2 | 2004 | 91 | 0.060 |
Why?
| | Third Ventricle | 1 | 2003 | 14 | 0.060 |
Why?
| | Motor Skills | 1 | 2024 | 85 | 0.060 |
Why?
| | Syndactyly | 1 | 2022 | 10 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2010 | 1752 | 0.060 |
Why?
| | Neurons, Afferent | 1 | 2023 | 89 | 0.060 |
Why?
| | Aggression | 1 | 2004 | 183 | 0.060 |
Why?
| | Neurologic Examination | 1 | 2003 | 126 | 0.050 |
Why?
| | Interneurons | 1 | 2023 | 103 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 111 | 0.050 |
Why?
| | Miniature Postsynaptic Potentials | 2 | 2014 | 9 | 0.050 |
Why?
| | X Chromosome Inactivation | 1 | 2022 | 21 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2003 | 203 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 531 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 136 | 0.050 |
Why?
| | Vocalization, Animal | 1 | 2021 | 29 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2023 | 148 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 37 | 0.050 |
Why?
| | Comorbidity | 2 | 2022 | 1525 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 194 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 253 | 0.050 |
Why?
| | Cerebral Palsy | 1 | 2022 | 80 | 0.050 |
Why?
| | Artifacts | 1 | 2001 | 125 | 0.050 |
Why?
| | Cohort Studies | 2 | 2021 | 5116 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 336 | 0.050 |
Why?
| | Genetic Testing | 1 | 2022 | 389 | 0.050 |
Why?
| | RNA Interference | 2 | 2014 | 460 | 0.050 |
Why?
| | Forecasting | 1 | 2001 | 352 | 0.050 |
Why?
| | Evoked Potentials, Auditory | 1 | 2021 | 201 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 453 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 556 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 521 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 1999 | 55 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 592 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2566 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 1999 | 84 | 0.040 |
Why?
| | Cost of Illness | 1 | 2020 | 258 | 0.040 |
Why?
| | Risk Factors | 3 | 2009 | 8998 | 0.040 |
Why?
| | Family | 1 | 2022 | 583 | 0.040 |
Why?
| | Risk Assessment | 1 | 2007 | 3055 | 0.040 |
Why?
| | Walking | 1 | 2022 | 414 | 0.040 |
Why?
| | Chronic Disease | 1 | 2004 | 1633 | 0.040 |
Why?
| | Benzothiadiazines | 1 | 2017 | 3 | 0.040 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.040 |
Why?
| | Emotions | 1 | 2022 | 495 | 0.040 |
Why?
| | Nifedipine | 1 | 2017 | 29 | 0.040 |
Why?
| | Dipeptides | 1 | 2017 | 51 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 456 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2005 | 1022 | 0.040 |
Why?
| | Quinoxalines | 1 | 2017 | 62 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 117 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2007 | 6555 | 0.040 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 1996 | 90 | 0.040 |
Why?
| | Language Tests | 2 | 2007 | 31 | 0.040 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 551 | 0.040 |
Why?
| | Awareness | 1 | 1997 | 93 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2009 | 105 | 0.030 |
Why?
| | Models, Biological | 1 | 2023 | 1715 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2018 | 290 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 280 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2001 | 384 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 1995 | 25 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2005 | 129 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 726 | 0.030 |
Why?
| | Dendritic Cells | 1 | 1998 | 442 | 0.030 |
Why?
| | Adenoviridae | 1 | 1996 | 191 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 1996 | 154 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1996 | 302 | 0.030 |
Why?
| | Peptides | 2 | 2016 | 879 | 0.030 |
Why?
| | Electric Stimulation | 2 | 2005 | 268 | 0.030 |
Why?
| | Mollusk Venoms | 1 | 1993 | 1 | 0.030 |
Why?
| | Ibotenic Acid | 1 | 1993 | 6 | 0.030 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 1993 | 11 | 0.030 |
Why?
| | Atrophy | 1 | 1994 | 164 | 0.030 |
Why?
| | Pyramidal Tracts | 1 | 1993 | 20 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 270 | 0.030 |
Why?
| | Neural Pathways | 2 | 2005 | 277 | 0.030 |
Why?
| | Heart Diseases | 1 | 1997 | 340 | 0.030 |
Why?
| | Point Mutation | 1 | 2014 | 228 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 16 | 0.030 |
Why?
| | Magnesium | 1 | 1993 | 150 | 0.030 |
Why?
| | Reading | 1 | 1994 | 157 | 0.030 |
Why?
| | Cerebral Infarction | 2 | 1989 | 45 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 395 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2009 | 814 | 0.030 |
Why?
| | Cyclic GMP | 1 | 2012 | 109 | 0.030 |
Why?
| | Cerebellum | 1 | 1994 | 203 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 8 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2014 | 828 | 0.030 |
Why?
| | Aging | 2 | 2021 | 1669 | 0.030 |
Why?
| | Memory, Episodic | 1 | 2012 | 42 | 0.030 |
Why?
| | Transfection | 2 | 2009 | 888 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 564 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2003 | 2235 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 408 | 0.030 |
Why?
| | Cyclic AMP | 1 | 2012 | 242 | 0.030 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 260 | 0.030 |
Why?
| | Levodopa | 1 | 1991 | 23 | 0.030 |
Why?
| | SOXB1 Transcription Factors | 1 | 2011 | 61 | 0.030 |
Why?
| | Trihexyphenidyl | 1 | 1991 | 1 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2025 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4551 | 0.020 |
Why?
| | Aphasia, Wernicke | 1 | 1989 | 2 | 0.020 |
Why?
| | Anomia | 1 | 1989 | 2 | 0.020 |
Why?
| | Aphasia, Broca | 1 | 1989 | 4 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 56 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1012 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 219 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 79 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 382 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 3 | 2004 | 2436 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 381 | 0.020 |
Why?
| | Dopamine | 1 | 2011 | 249 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2009 | 52 | 0.020 |
Why?
| | Germ Cells | 1 | 2009 | 64 | 0.020 |
Why?
| | Calcineurin | 1 | 2009 | 95 | 0.020 |
Why?
| | Austria | 1 | 2008 | 2 | 0.020 |
Why?
| | Switzerland | 1 | 2008 | 27 | 0.020 |
Why?
| | Netherlands | 1 | 2008 | 62 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 174 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 467 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 154 | 0.020 |
Why?
| | Probability | 1 | 2009 | 305 | 0.020 |
Why?
| | Germany | 1 | 2008 | 89 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 468 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 307 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 360 | 0.020 |
Why?
| | Alcoholism | 1 | 1994 | 717 | 0.020 |
Why?
| | Picrotoxin | 1 | 2007 | 14 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 1988 | 100 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2007 | 33 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1988 | 86 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 253 | 0.020 |
Why?
| | United States | 1 | 2023 | 12541 | 0.020 |
Why?
| | Electromyography | 1 | 2008 | 326 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 4908 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 823 | 0.020 |
Why?
| | Solute Carrier Family 12, Member 2 | 1 | 2005 | 7 | 0.020 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2005 | 9 | 0.020 |
Why?
| | Phenobarbital | 1 | 2005 | 18 | 0.020 |
Why?
| | Brain Mapping | 1 | 1989 | 532 | 0.020 |
Why?
| | Electric Capacitance | 1 | 2005 | 7 | 0.020 |
Why?
| | Turtles | 1 | 2005 | 11 | 0.020 |
Why?
| | Sclerosis | 1 | 2005 | 14 | 0.020 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2005 | 4 | 0.020 |
Why?
| | Head Movements | 1 | 2005 | 18 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 105 | 0.020 |
Why?
| | Egtazic Acid | 1 | 2005 | 44 | 0.020 |
Why?
| | Videotape Recording | 1 | 2005 | 32 | 0.020 |
Why?
| | Synaptic Vesicles | 1 | 2005 | 38 | 0.020 |
Why?
| | Cadmium | 1 | 2005 | 62 | 0.020 |
Why?
| | Basal Ganglia | 1 | 2005 | 44 | 0.020 |
Why?
| | Aspartic Acid | 1 | 2005 | 86 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2005 | 140 | 0.020 |
Why?
| | Chelating Agents | 1 | 2005 | 74 | 0.020 |
Why?
| | Neural Conduction | 1 | 2005 | 81 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2005 | 146 | 0.020 |
Why?
| | Rotation | 1 | 2005 | 121 | 0.020 |
Why?
| | Video Recording | 1 | 2005 | 156 | 0.020 |
Why?
| | Posture | 1 | 2005 | 158 | 0.020 |
Why?
| | Reference Values | 2 | 1999 | 774 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2011 | 2275 | 0.020 |
Why?
| | Acyclovir | 1 | 2004 | 105 | 0.020 |
Why?
| | Vomiting | 1 | 2004 | 123 | 0.020 |
Why?
| | Drug Interactions | 1 | 2005 | 351 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1570 | 0.010 |
Why?
| | Attention | 1 | 2007 | 408 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2424 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2003 | 43 | 0.010 |
Why?
| | Fever | 1 | 2004 | 283 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 294 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1944 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2326 | 0.010 |
Why?
| | Computer Simulation | 1 | 2005 | 922 | 0.010 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 1999 | 5 | 0.010 |
Why?
| | Colorado | 1 | 2009 | 4193 | 0.010 |
Why?
| | Water | 1 | 2003 | 425 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1664 | 0.010 |
Why?
| | Disease Progression | 1 | 2005 | 2490 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 399 | 0.010 |
Why?
| | Dizocilpine Maleate | 1 | 1996 | 16 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 205 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 1996 | 65 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1308 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1624 | 0.010 |
Why?
| | Brain Concussion | 1 | 1999 | 470 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1047 | 0.010 |
Why?
| | Receptors, Dopamine | 1 | 1991 | 13 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1991 | 64 | 0.010 |
Why?
| | Psychological Tests | 1 | 1991 | 129 | 0.010 |
Why?
| | Frontal Lobe | 1 | 1991 | 148 | 0.010 |
Why?
| | Kidney | 1 | 1996 | 1353 | 0.010 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 48 | 0.000 |
Why?
| | Hypertension | 1 | 1988 | 1203 | 0.000 |
Why?
|
|
Benke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|